Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein,

Slides:

Advertisements

Similar presentations

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

Advertisements

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Omalizumab for the treatment of chronic spontaneous urticaria: A meta-analysis of randomized clinical trials Zuo-Tao Zhao, MD, PhD, Chun-Mei Ji, M Pharm,

Responsiveness and minimal important difference of the urticaria control test Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

CHRONIC IDIOPATHIC URTICARIA

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

Thomas B. Casale, MD, Patrick H. Win, MD, Jonathan A

Findings from an Online Survey Assessing the Burden and Management of Seasonal Allergic Rhinoconjunctivitis in US Patients Eli O. Meltzer, MD, Judith.

Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema Richard Sinert, DO, Phillip Levy, MD, MPH,

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria Ragip Ertas, MD, Kemal Ozyurt,

Chronic rhinosinusitis: Potential new use for topical sulfasalazine

Fanny Legrand, PhD, PharmD, Amy D. Klion, MD

Dennis K. Ledford, MD, Sally Wenzel, MD

Shyam Joshi, MD, David A. Khan, MD

Jennie Gane, MBChB (Hons), MSc, Roger Buckley, BM BCh, MA, FRCS

Tiotropium add-on therapy improves lung function in children with symptomatic moderate asthma Christian Vogelberg, MD, PhD, Michael Engel, MD, István.

Biologic Therapy and Novel Molecular Targets of Severe Asthma

Desensitization to Chemotherapeutic Agents

Intramuscular Versus Intravenous Immunoglobulin Replacement Therapy and Measurement of Immunoglobulin Levels During Immunoglobulin Replacement Therapy

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD

Pavel Kolkhir, MD, Martin K

Marcus Shaker, MD, MS, Tsuzumi Kanaoka, BA, Robert G. P

Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy Allen Kaplan, MD, Dennis Ledford,

Predicting Chronic Spontaneous Urticaria Symptom Return After Omalizumab Treatment Discontinuation: Exploratory Analysis Marta Ferrer, MD, PhD, Ana Giménez-Arnau,

Practice Notes from the AAAI

An Infant with Atopic Dermatitis and Itching After Ingestion of Milk

Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial Martin Metz, MD, Andrea Schütz, MD, Karsten Weller, MD, Marina.

Effect of Omalizumab on Blood Basophil Counts in Patients with Chronic Idiopathic/Spontaneous Urticaria Sarbjit S. Saini, Theodore A. Omachi, Benjamin.

A randomized multicenter study evaluating Xolair persistence of response after long- term therapy Dennis Ledford, MD, William Busse, MD, Benjamin Trzaskoma,

Asthma Exacerbations and Triggers in Children in TENOR: Impact on Quality of Life Bradley E. Chipps, MD, Tmirah Haselkorn, PhD, Karin Rosén, MD, PhD,

Lip edema Journal of the American Academy of Dermatology

Validation of the Pregnancy Asthma Control Test

Timothy J. Craig, DO, H. Henry Li, MD, Marc Riedl, MD, Jonathan A

Treatment of chronic autoimmune urticaria with omalizumab

A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine–refractory chronic idiopathic urticaria

Nonadherence to Asthma Treatment: Getting Unstuck

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study Thomas B. Casale, MD, Allan.

Successful treatment of idiopathic angioedema with ecallantide

Consistently very poorly controlled asthma is associated with greater activity and school impairment in children with severe or difficult-to-treat asthma

Aimee L. Speck, MD, Michael Hess, MSI, Alan P. Baptist, MD, MPH

Omalizumab, an Anti-IgE mAb, Receives Approval for the Treatment of Chronic Idiopathic/Spontaneous Urticaria Keith C.P. Wu, Zarif K. Jabbar-Lopez Journal.

Change in Asthma Control Over Time: Predictors and Outcomes

Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized,

The Emperor Has No Symptoms: The Risks of a Blanket Approach to Using Epinephrine Autoinjectors for All Allergic Reactions Paul J. Turner, FRACP, PhD,

News & Notes Journal of Allergy and Clinical Immunology

Double-Blind Placebo-Controlled Trial of Dapsone in Antihistamine Refractory Chronic Idiopathic Urticaria Matt Morgan, MD, Andrew Cooke, MD, Laura Rogers,

The Management of Eosinophilic Esophagitis

Russell S. Traister, MD, PhD, Merritt L

Justin R. Chen, MD, Brett L. Buchmiller, MD, David A. Khan, MD

Nicola A. Hanania, MB BS, MS, Bradley E. Chipps, MD, Noelle M

Neetu Talreja, MD, Richard F. Lockey, MD

Mapping the Asthma Care Process: Implications for Research and Practice Alexandra Lelia Dima, PhD, Marijn de Bruin, PhD, Eric Van Ganse, MD, PhD, FRCP

Pinja Ilmarinen, PhD, Leena E

Real-world attitudes among allergists/immunologists regarding oral immunotherapy and preferred terminology Bradley E. Chipps, MD, Christina E. Ciaccio,

Sharon Seth, MD, David A. Khan, MD

Cephalosporin Side Chain Cross-reactivity

Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria Janine Gericke, PhD, Martin Metz, MD, Tatevik Ohanyan,

News & Notes Journal of Allergy and Clinical Immunology

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria Katja Koch, Karsten Weller, MD, Andreas Werner,

Practice Notes from the AAAI

Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab Aidan Long, MD, Abdelkader Rahmaoui, MD, Kenneth.

Pınar Uysal, MD, Esben Eller, MSc, PhD, Charlotte G

Footnotes1 Journal of Allergy and Clinical Immunology

Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor–Induced Upper Airway Angioedema Richard Sinert, DO, Phillip Levy, MD, MPH,

What Is Chronic Cough? Terminology

Pedro Giavina-Bianchi, MD, PhD, Shih-Wen Huang, MD

News & Notes Journal of Allergy and Clinical Immunology

The effects of an H3 receptor antagonist (PF ) with fexofenadine on reducing allergic rhinitis symptoms Jeffrey R. Stokes, MD, Francisco A. Romero,

Lisa A. Beck, MD, Sarbjit Saini, MD

Presentation transcript:

Similar Efficacy with Omalizumab in Chronic Idiopathic/Spontaneous Urticaria Despite Different Background Therapy Thomas B. Casale, MD, Jonathan A. Bernstein, MD, Marcus Maurer, MD, Sarbjit S. Saini, MD, Benjamin Trzaskoma, MS, Hubert Chen, MD, Clive E. Grattan, MA, MD, FRCP, Ana Gimenéz-Arnau, MD, PhD, Allen P. Kaplan, MD, Karin Rosén, MD, PhD The Journal of Allergy and Clinical Immunology: In Practice Volume 3, Issue 5, Pages 743-750.e1 (September 2015) DOI: 10.1016/j.jaip.2015.04.015 Copyright © 2015 The Authors Terms and Conditions

Figure 1 Study designs. CIU, Chronic idiopathic urticaria; CSU, chronic spontaneous urticaria; LTRA, leukotriene receptor antagonist. The Journal of Allergy and Clinical Immunology: In Practice 2015 3, 743-750.e1DOI: (10.1016/j.jaip.2015.04.015) Copyright © 2015 The Authors Terms and Conditions

Figure 2 Proportion of responders by treatment group. *P < .0001. †P = .002. UAS7, urticaria activity score over 7 d. Results for the GLACIAL study from Kaplan et al.11 The Journal of Allergy and Clinical Immunology: In Practice 2015 3, 743-750.e1DOI: (10.1016/j.jaip.2015.04.015) Copyright © 2015 The Authors Terms and Conditions

Figure 3 Percent reductions in key endpoints from baseline to week 12. *P < .0001. †P = .034. DLQI, Dermatology Life Quality Index; ISS, itch severity score; UAS7, urticaria activity score over 7 d. The Journal of Allergy and Clinical Immunology: In Practice 2015 3, 743-750.e1DOI: (10.1016/j.jaip.2015.04.015) Copyright © 2015 The Authors Terms and Conditions